Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage. It comprehensively assesses the clinical outcomes of the patients and aims to compare the clinical efficacy and safety of icoxib as a combined add-on treatment versus simple hormone shock therapy during the acute phase of NMOSD.Using simple hormone shock therapy (IVMP) as the control group, the efficacy and safety of etanercept treatment in the acute attack phase of Chinese patients with AQP4-positive neuromyelitis optica spectrum disorder (NMOSD) were evaluated.

NCT Number	NCT07410039
Lead Sponsor	Chinese PLA General Hospital
Conditions	Neuromyelitis Optica Spectrum Disorder Attack
Enrollment	200 participants
Start Date	2026-02-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-12